Adjuvant crizotinib in high-risk uveal melanoma following definitive therapy

INTRODUCTION: Approximately 40% of patients with uveal melanoma (UM) will develop metastatic disease. Tumors measuring at least 12mm in basal diameter with a class 2 signature, as defined by a widely used gene expression-profiling test, are associated with significantly higher risk of metastasis, wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Shaheer, Lutzky, Jose, Shoushtari, Alexander N., Jeter, Joanne, Marr, Brian, Olencki, Thomas E., Cebulla, Colleen M., Abdel-Rahman, Mohamed, Harbour, J. William, Sender, Naomi, Nesson, Alexandra, Singh-Kandah, Shahnaz, Hernandez, Susana, King, Jeanelle, Katari, Manpreet S., Dimapanat, Lyssa, Izard, Stephanie, Ambrosini, Grazia, Surriga, Oliver, Rai, Alex J., Chiuzan, Codruta, Schwartz, Gary K., Carvajal, Richard D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9465386/
https://www.ncbi.nlm.nih.gov/pubmed/36106113
http://dx.doi.org/10.3389/fonc.2022.976837

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9465386/
https://www.ncbi.nlm.nih.gov/pubmed/36106113
http://dx.doi.org/10.3389/fonc.2022.976837

Ejemplares similares